Is Trientine currently on the market in the country?

Trientine（Trientine） has not been officially launched in mainland China, nor has it been approved by the National Medical Products Administration (NMPA) to be included in the Chinese Drug List. Since trientine is a specialized drug mainly used to treat Wilson's disease, a rare disease, its domestic demand is relatively low, which is part of the reason why it has not been widely introduced. At the same time, China still mainly relies on penicillamine as the drug of choice for Wilson's disease. Although some patients have adverse reactions to penicillamine, it is still a commonly used clinical solution due to its long-term use experience and high accessibility.

In the context of not being marketed in China, some patient families may obtain trientine through overseas purchasing agents or cross-border medical channels, especially when penicillamine is not tolerated or has poor efficacy. It should be noted that the use of unapproved drugs has many potential risks, including unknown sources, irregular dosages, and lack of monitoring methods. In addition, trientine has not yet entered China's medical insurance system, so the financial burden of its acquisition and long-term use is also an important challenge faced by patients and families.

However, as the country gradually establishes a green channel for the review and approval of rare disease drugs and continues to pay attention to the accessibility of rare disease drugs, the possibility of trientine being launched in China in the future is gradually increasing. In particular, in recent years, my country has paid increasing attention to rare diseases such as Wilson's disease. The national level has issued a number of policies to encourage the introduction of foreign innovative drugs, which is expected to open the market for many rare disease drugs, including trientine. For patients who urgently need such drugs, it is recommended to evaluate other available alternative drugs under the guidance of a doctor. At the same time, they can pay attention to the dynamics of domestic and foreign clinical trials or special approval channels in order to obtain safe and legal treatment support.

Reference materials:https://www.cufence.com/